Anuh Pharma (506260) Q3 2026 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter and nine months ended 31 December 2025, with review by statutory auditors and audit committee.

• Authorization granted to key managerial personnel for materiality determination and stock exchange disclosures.

Financial highlights

• Revenue from operations for Q3 FY26 was ₹19,717.81 lakhs, up from ₹15,951.33 lakhs in Q3 FY25.

• Net profit after tax for Q3 FY26 stood at ₹1,345.10 lakhs, compared to ₹1,034.31 lakhs in Q3 FY25.

• EBITDA for Q3 FY26 was ₹2,091.04 lakhs (10.60% margin), up from ₹1,572.71 lakhs (9.86%) in Q3 FY25.

• Basic and diluted EPS for Q3 FY26 was ₹1.34, compared to ₹1.03 in Q3 FY25.

Outlook and guidance

• Company continues to monitor regulatory changes, especially regarding new labour codes, and will adjust accounting as needed.